Safety and Effectiveness of Sebetralstat for Short-Term Prevention Before Procedures in People With Hereditary Angioedema
This is a Phase 4, prospective, open-label trial to evaluate the safety and effectiveness of sebetralstat when used for STP for a qualifying procedures in patients 12 years of age or older with hereditary angioedema (HAE).
Male or female patients ≥12 years of age at time of Screening [+8]
A clinically significant history of poor response to bradykinin receptor 2 block... [+8]